Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
51 /100
HIGH RISK
Score updated Aug 28, 2026

NEUP — Neuphoria Therapeutics Inc. Dilution Risk Tracker

Track NEUP dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NEUP — Get alerts when the score changes →

As of August 28, 2026, Neuphoria Therapeutics Inc. (NEUP) has a DilutionWatch DilutionScore of 51/100, rated HIGH dilution risk. Neuphoria Therapeutics Inc. has a market capitalization of $28.70M, 5.40M shares outstanding, 19 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰Cash Runway
📊 Float Risk
27
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for NEUP.
🔔 Track NEUP — Get forecast alerts →

Market Data

Market Cap$28.70M
Shares Outstanding5.40M
Float4.19M
Cash$19.44M
Debt$34.2K
Short InterestN/A

Institutional Holdings

QoQ: ↑ 17.1% shares (2026Q1 vs prior)
19 institutional holders · 1.76M shares
#1 Lynx1 Capital Management LP 875.3K shares
#2 AdvisorShares Investments LLC 155.4K shares
#3 Shay Capital LLC 151.0K shares
+ 16 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest65.5K
Days to Cover1.0
% of Float1.6%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-06-30
Full SEC filing analysis available with free account

Recent News

No recent news

Factual NEUP Dilution Snapshot

Neuphoria Therapeutics Inc. (NEUP) has a DilutionScore of 51/100, rated High dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track NEUP Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking NEUP — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for NEUP
NEUP FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.